-
2024-515861-33-00
4
2025-03-25
Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, an
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-508307-21-00
5
2025-03-19
Prader-Willi syndrome
-
2024-515252-20-00
9
2025-03-14
Myelofibrosis (MF) unresponsive to JAK inhibitors
-
2024-513547-82-00
5
2025-03-11
Transthyretin Amyloidosis
-
2022-501315-13-00
5
2025-03-06
Patients with lateralised oropharyngeal, laryngeal and hypopharyngeal
-
2023-509234-19-00
4
2025-03-03
Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-s
-
2024-517262-41-00
5
2025-02-28
Juvenile Psoriatic Arthritis (JPsA)
-
2024-515020-36-00
9
2025-02-24
Advanced Solid tumour
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2022-502352-31-00
5
2025-02-10
Colorectal Cancer (CRC)
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2024-515934-34-00
6
2025-01-28
Low-cardiac output syndrome (LCOS)
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2024-511377-30-00
10
2025-01-23
SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
-
2024-511775-15-00
4
2025-01-17
Immune system diseases
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2024-516450-21-00
6
2024-12-31
metastatic or locally advanced urothelial cancer
-
2022-501547-33-01
11
2024-12-24
Acute myocarditis
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-510147-37-00
6
2024-12-18
Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairmen
-
2024-518092-62-00
5
2024-12-09
Adult critically ill patients requiring non-invasive (NIMV) or invasiv